Please try another search
For the six months ended 30 June 2020, Myokardia Increvenues was not reported. Net loss increased 76% to$133.5M. Higher net loss reflects Research and development- Balancing increase of 82% to $85.7M (expense), Generaland administrative - Balancing increase of 57% to $29.1M(expense), Stock-based Compensation in R&D increase of 56%to $10.5M (expense). Basic Earnings per Share excludingExtraordinary Items decreased from -$1.75 to -$2.78.
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | 0 | |||
Operating Income | -85.4 | -64.58 | -71.78 | -61.41 |
Net Income | -84.74 | -63.59 | -69.87 | -58.77 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 1035.66 | 998.73 | 441.33 | 456.09 |
Total Liabilities | 190.68 | 90.09 | 92.23 | 49.82 |
Total Equity | 844.98 | 908.64 | 349.1 | 406.27 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -142.24 | -112.76 | -59.9 | -241.77 |
Cash From Investing Activities | 92.81 | 56.56 | 87.85 | -181.16 |
Cash From Financing Activities | 623.91 | 613.9 | 1.82 | 278.3 |
Net Change in Cash | 574.48 | 557.7 | 29.77 | -144.63 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review